Our Mission is to make lab testing accessible and immediate.

Genalyte brings laboratory testing to the patient and physician. 
Our goal is to provide onsite, real-time laboratory results for 89% of blood tests that primary care physicians typically order.
All results are reviewed through our cloud-based central lab before releasing them back to the physician for review and discussion with their patients.


Our leadership team draws on diverse backgrounds spanning healthcare and technology.




Ashraf Hanna is the Chief Executive Officer at Genalyte. 

Ashraf joined Genalyte as Chief Executive Officer from Verily, an Alphabet company, where he was Chief Operating Officer.  Among other activities, he helped lead the company to obtain its first 510k approval and expand Covid testing sites during the pandemic.  Prior to Verily, Ashraf was the CEO at ORIC Pharmaceuticals, a company focused on developing drugs for resistant cancers.   Ashraf led the company from concept through preclinical and the beginning of Phase 1 clinical trials.  ORIC had an IPO at approximately $1B valuation while still in Phase 1.   Ashraf spent over a decade at Genentech as Vice President and head of Alliance Management, Portfolio Prioritization, and head of Commercial and Medical Affairs Finance.  He started his work career at McKinsey and Company. 

Ashraf has a PhD in Physics from Harvard, and an M.D. from the University of Massachusetts and studied Physics and Economics as an undergraduate at the University of Chicago.  



Senior VP of Technology Development

Kevan brings nearly 25 years experience in life sciences technology research, development and commercialization. He started his career at Pacific Biosciences, a small, venture backed genomics startup and grew with the company through its first customer shipment and IPO.  While there his work included basic research, manufacturing process development, enterprise IT system implementation and program management of multiple new product development programs. After PacBio, Kevan spent more than a decade in a variety of leadership roles at Illumina where he led multiple new product development programs and supervised research and engineering teams across the life sciences disciplines. Most recently, Kevan was responsible for a custom products, application development and partnerships team driving more than $300M in annual revenue.

Kevan holds a PhD in Applied and Engineering Physics from Cornell University and an MBA from The Wharton School, and was an undergrad at the University of Illinois at Urbana where he earned a BS in Physics and a BS in Computer Science and Mathematics. 

Rachel Larrenaga, J.D., Esq.

Rachel Larrenaga, J.D., Esq.

General Counsel

Rachel is responsible for overseeing all legal affairs at Genalyte including commercial transactions, business development transactions, intellectual property, corporate governance and compliance.  Rachel brings extensive legal experience over an 18-year career, in commercial negotiations, intellectual property licensing, acquisitions and venture-backed financing.  

Most recently, Rachel was Vice President of Legal at ChargePoint, one of the leaders in electric vehicle charging. She joined ChargePoint in 2014 as its second legal hire and helped grow the organization thru its recent transition to a public company in March 2021.  Rachel helped build  the entire North America commercial team and was responsible for negotiating high risk and high reward contracts.  Before going in-house, Rachel worked as a senior associate at Orrick Herrington and Sutcliffe and Murray & Murray. 

Rachel holds a BA from UC Davis (Summa Cum Laude) and a J.D. from UC Hastings (Magna Cum Laude, Order of the Coif).  Rachel is admitted to both the California and Texas State Bars.



VP of Quality and Regulatory Functions

David joined Genalyte from Lucira Health, a diagnostic test developer, where he served as their Vice President of Regulatory and Clinical Affairs where successfully obtained the FDA’s first emergency use authorization for an at-home COVID-19 & Flu test, as well securing the first approval for their combination COVID & Flu Test by Health Canada and TGA (Australia).

Prior to joining Lucira Health, Davd spent the last 15 years in the Medical Device industry leading the Quality & Regulatory teams at companies such as Philips, DJO Global, Alphatec Spine and Henry Schein Orthodontics.  Prior to his medical industry experience, David spent 16 years in the automotive and aerospace industries at Ford Motor Company, General Dynamics and Northup Grumman.

David received a B.S. from San Diego State University in Electrical Engineering, a Masters of Science in Reliability Engineering from the University of Maryland, and is a Certified Six Sigma Black Belt.



VP of Finance and People Operations

Sam Rutten oversees all aspects of financial operations at Genalyte. He brings more than 15 years of finance and accounting experience with public and private companies in the life science and technology industries. Sam also leads administration operations and plays a major leadership role in the Company’s business strategy. 

Sam has extensive operational leadership experience raising venture capital and developing strategic financial plans. He most recently served as Head of Finance and Controller at Roswell Biotechnologies where he led financial operations and was responsible for the IPO and commercialization readiness planning. Prior to that, Sam was with Fate Therapeutics where he led SEC reporting and SOX 404b implementation during the company’s rapid growth.

Before transitioning in-house, Sam worked as a senior business assurance associate at Moss Adams and Baker Tilly, where he worked with private and public life science clients. He holds a certified public accounting license and received a B.S. degree in corporate finance and accounting from the University of Wisconsin, La Crosse.



VP of Software Engineering

Dmitriy has a B.S. in Computer Engineering from UCSD and a Masters in Medical Device Engineering from UCSD also.

Dmitriy started his career working on software in the vehicle telematics space where he developed vehicle-to-vehicle and vehicle-to-infrastructure communications systems. He then moved into the medical device world.
Dmitriy held positions at Hospira as a tech lead leading development on one of the infusion pump platforms followed by a role as a tech-lead of the connectivity platform development at Outset Medical in support of their Tablo Dialysis system.
He then led platform software engineering teams at Auris Health, responsible for robotics and controls, infrastructure, platform software, data collection, operating systems, CI/CD etc. Some time after J&J acquired Auris, Dmitriy left to start his own venture (TraceMatrix) where his team developed a content management system with traceability for regulated industries. He sold/merged this company witn Enlil (Enlil.com) where he continued spearheading this development in a capacity of Sr Director of Product Development. After spending one year at Enlil following the acquisition, Dmitriy started with Genalyte where he leads the software organization in all areas pertaining to embedded, application, cloud and infrastructure, CI/CD development as well as software QA and regulatory compliance.



Director of Communications and Government Affairs

Alexah Boyer is the Director of Communications and Government Affairs at Genalyte, leading grant efforts, communications, and investor relations.

Alexah joined Genalyte from Capitol Hill where she worked for several Members of Congress as Communications Director and Policy Advisor on biotech, cybersecurity, and national defense policy. 

In addition to her time in the public sector, Alexah started a political consulting firm, advising clientele from elected Members of Congress to presidential candidates on communications and fundraising strategies. 

Alexah attended National Defense University in Washington, D.C along with CSU, Sacramento where she studied Government & International Affairs while working for former Governor Jerry Brown.



Senior Director of In Vitro Diagnostics and Clinical Regulatory

Sasi Mudumba is Genalyte’s Senior Director of In Vitro Diagnostics and Clinical Regulatory, responsible for managing the development and regulatory submission.

She led Genalyte’s two FDA approvals and with her prior employer, has taken 11 products through the FDA approval process.

After earning her Ph.D. in Biotechnology from Jawaharlal Nehru Technological University, her career has included several biotech companies including NoAb BioDiscoveries and SQI Diagnostics

Board of Directors



Ashraf Hanna is the Chief Executive Officer of Genalyte.

Ashraf joined Genalyte as Chief Executive Officer from Verily, an Alphabet company, where he was Chief Operating Officer. Among other activities, he helped lead the company to obtain its first 510k approval and expand Covid testing sites during the pandemic. Prior to Verily, Ashraf was the CEO at ORIC Pharmaceuticals, a company focused on developing drugs for resistant cancers. Ashraf led the company from concept through preclinical and the beginning of Phase 1 clinical trials. ORIC had an IPO at approximately $1B valuation while still in Phase 1. Ashraf spent over a decade at Genentech as Vice President and head of Alliance Management, Portfolio Prioritization, and head of Commercial and Medical Affairs Finance. He started his work career at McKinsey and Company. Ashraf has a PhD in Physics from Harvard, and an M.D. from the University of Massachusetts and studied Physics and Economics as an undergraduate at the University of Chicago.


Member, Board of Directors

Andrew Conrad, PhD, is the Chief Executive Officer, Chairman and Founder of Verily where he oversees an integrated team of engineers, scientists, designers, and medical experts working on a wide spectrum of healthcare-related projects.
Previously, he was Chief Scientific Officer of Laboratory Corporation of America (LabCorp). Dr. Conrad co-founded the National Genetics Institute, where he served as Chief Scientific Officer. He is a Working Group Member on the Precision Medicine Initiative and a member of the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI) Scientific Advisory Board.


Chairman, Board of Directors

Jeff Huber is the Founding CEO and Vice Chairman of GRAIL (2016-present). GRAIL’s mission is to detect cancer early, when it can be cured.

Prior to GRAIL, Jeff was a Senior Vice President at Google. Over 13 years at Google, Jeff co-founded Google’s life sciences efforts in Google[x] (2013-2016), and led development and scaling for Google Maps (2011-2013), Google Apps (2005-2010), and Google Ads (2003-2011). During his tenure as an executive at Google, Jeff oversaw 50x growth in revenues (from $1 billion to >$50 billion) and organization (1,000 to >50,000 employees), and managed a $5 billion P&L and large distributed teams (5,000+ direct-line employees). Earlier, Jeff was vice president of architecture and systems development at eBay and senior vice president of engineering at Excite@Home, where he led consumer product and infrastructure development.

Jeff was recognized as one of the ‘100 Most Intriguing Entrepreneurs’ (2017), and is an active early-stage investor/advisor in breakthrough life sciences and technology, including Openwater, Mammoth Biosciences, Vir, Sana, Zymergen, Atomwise, Genalyte, Pinterest, Honor, OpenDoor, and AngelList.

Jeff holds a bachelor’s degree in computer engineering from the University of Illinois, where he was Commencement Speaker (2016) and received a ‘Distinguished Alumni Award’ from the College of Electrical & Computer Engineering (2018) for ‘challenging the status quo through innovation’. He also holds a master’s degree in business from Harvard University. Jeff is a board member of GRAIL (Vice Chairman), Genalyte (Chairman), Electronic Arts (EA), Openwater, and The Exploratorium, and a former board member of Illumina (ILMN; 2014-2016).


Member, Board of Directors

Rob Faulkner is the Managing Director of RedMile Group, a healthcare investment organization that makes venture, growth, and crossover investing across healthcare.

Rob has been an equity analyst in the medical device industry since 1994. His coverage areas have included, among others, cardiology, orthopedics, urology, vision care, aesthetic surgery and diabetes. Rob has held positions with Thomas Wiesel Partners, Prudential Financial and J.P. Morgan Chase & Co. Rob began his career on Wall Street at S.G. Warburg & Co. (now UBS) where he covered biotechnology and medical device stocks for three years. Prior to moving to sell-side research, he spent two years with The Wilkerson Group (now IBM), a consulting firm specializing in the assessment of the value of healthcare technologies.

Rob graduated from the Tuck School of Business at Dartmouth College and Harvard University.


Member, Board of Directors

Rajesh is a Partner at Khosla Ventures. Rajesh brings with him two decades of experience assisting and investing in deeptech/ hardware startups across many industries including Cleantech and Healthcare.
Before joining Khosla Ventures, Rajesh served as the Head of Applied Ventures LLC, the Venture Capital arm of Applied Materials, where he managed a portfolio of over 85 hardware startups across 13 countries. Rajesh also drove the establishment of an $850M Materials Engineering Technology Accelerator (META) facility in NY, to enable access of semiconductor fabs for startups. Rajesh received Global Corporate Venturing’s (GCV) Powerlist award in 2019.

Before joining Applied Ventures, Rajesh worked at the venture arm of Third Point LLC. Previously, at Lucent’s Bell Labs, he drove the technical assessment & partnerships with several Photonics, MEMS and RF startups. Rajesh also led the design for reliability program for Lucent’s 10Gb/s and 40Gb/s telecommunication systems and supported the successful deployment of these systems globally.

While pursuing his MBA at Harvard Business School, Rajesh interned at Deutsche Bank’s cleantech investment banking group. Rajesh completed his M.S. at the University of Maryland at College Park, and received his Bachelor’s degree in Chemical Engineering from IIT Madras where he was awarded the Shankar Dayal Sharma (President of India) Medal for overall excellence.


Member, Board of Directors

Dr. El Assal is a scientist-clinician turned venture capitalist investing in healthcare and life sciences. He is the Managing General Partner & Co-founder of Boutique Venture Partners, a venture capital firm that specializes in early-stage investments in Biotech, Medtech, Digital Health, Health Economics, and Health Edtech startups. Rami and his partners launched the Early Disease Detection and Early Treatment Fund, which is recognized in the industry as one of the earliest vehicles focusing on early detection and treatment, and is dedicated to translating the most promising innovations originating from esteemed research labs. In 2022, he was selected to be amongst the Top Healthcare Investors by GrowthCap Advisory.

Prior to founding Boutique, Rami was a Research Scientist (Academic Staff) at the Canary Center for Cancer Early Detection at Stanford University School of Medicine, and is currently affiliated with the Precision Health and Integrated Diagnostic Center at Stanford University. Previously, he completed two Postdoctoral Research Fellowships at Stanford and Harvard Medical Schools. He has been recognized by several entities, such as the Center of Nanoscale Systems (CNS) at Harvard University, and published in the field of Early Detection & Early Treatment, including a two-volume book published in Springer Nature.


Member, Board of Directors

Saeid is the Managing Director at HBM Genomics investing in world-class entrepreneurs in life sciences companies.

He has more than 25 years of experience as an entrepreneur building successful biotech companies from scratch. Saeid is an active investor/advisor in leading life sciences companies, including Genalyte, Clear Labs, Convergent Genomics, Encoded Therapeutics, Haystack Biosciences, Seer Biosciences, Trace Genomics, and Xcell Biosciences.

Prior to HBM Genomics, Saeid was the founder, President & CEO of NextBio which was acquired by Illumina in 2013. Prior to founding NextBio, he was the President & CEO of Silicon Genetics which was acquired by Agilent in 2004. Mr. Akhtari has also held executive management positions at several other life sciences companies.


Member, Board of Directors

Joe Markee Managing Director at Express Ventures

Joe brings extensive experience in early stage company formation, capital raising, corporate management, and public and private corporate governance. Joe’s startup experience encompasses Primary Access as a founder and senior manager, Copper Mountain Networks as founding CEO, CTO and Chairman, Figure 8 Wireless as CEO and StackIQ as CEO and Chairman.

Joe was also a founder and served as President of the San Diego Telecommunications Council (renamed CommNexus). He has been honored with awards for his contributions to San Diego’s high-tech business community, including Master Entrepreneur.


Member, Board of Directors

Dr. Cary Gunn has been blazing trails in the technology community for almost 30 years.

Prior to founding Genalyte, Cary served as co-founder and Chief Technical Officer of Luxtera, a developer of innovative optical solutions; his military career includes almost 10 years in the United States Air Force, where he was responsible for launching GPS satellites. Holding 81 (and counting) issued U.S. patents, Cary has been recognized in publications including the MIT Technology Review, which named him a Top Young Innovator in 2003. Five years later, Cary’s achievements in silicon photonics were awarded with the Optical Society of America Adolph Lomb Medal and the Berthold-Leibinger Foundation Innovation Prize. He received his bachelor’s degree in Applied Physics and Organic Chemistry from the United States Air Force Academy and his PhD in Electrical Engineering from the California Institute of Technology (Caltech).